Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2025
Cost-Effectiveness of Reorganizing the Approach to Diabetes Through the Application of Registries: An Innovative Model to Organize Diabetes Care in First Nations Communities in Canada.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ghule Priyanka, Rashid Ishfaq, Minhas-Sandhu Jasjeet K, Crowshoe Lynden, Johnson Jeffrey A, Samanani Salim, Dubois Cerina, Asche Carl V, Eurich Dean T
Аннотация
OBJECTIVES: The Reorganizing the Approach to Diabetes through the Application of Registries (RADAR) is an innovative care model incorporating a disease registry and electronic health record tailored for First Nations people in Alberta, Canada. Given its success in improving health outcomes, this study evaluates RADAR's cost-effectiveness compared with standard diabetes care in First Nations populations with type 2 diabetes.
METHODS: The United Kingdom Prospective Diabetes Study Outcomes Model 2 was used to project clinical and cost outcomes over 25 years. Demographics and clinical parameters were used as input parameters. Costs (for RADAR and complications) and utility estimates were derived from the literature. Outcome measures included life-years, quality-adjusted life-years (QALY's), and total and complication costs. Base-case analysis was conducted for eligible patients with type 2 diabetes ≥ 18 years using a Canadian payer perspective with a 25-year time horizon. Future costs and effects were discounted at 3% annually.
RESULTS: RADAR clients experienced higher QALYs (12.69 vs 12.47) than those receiving baseline care. The total cost for RADAR clients (n = 516) was $3971 more per client compared with baseline care. Over the modeled time horizon, the total discounted costs (client management and complications) were higher for RADAR clients than for those receiving baseline care ($16 165 vs $14 463), yielding an incremental cost-effectiveness ratio of $8105 per QALY for RADAR users relative to baseline.
CONCLUSIONS: Our analyses showed that RADAR is potentially cost-effective if the willingness-to-pay threshold of $50 000 per QALY is considered as per the Canadian Agency for Drugs and Technologies in Health guidelines, supporting its value in First Nations care.
METHODS: The United Kingdom Prospective Diabetes Study Outcomes Model 2 was used to project clinical and cost outcomes over 25 years. Demographics and clinical parameters were used as input parameters. Costs (for RADAR and complications) and utility estimates were derived from the literature. Outcome measures included life-years, quality-adjusted life-years (QALY's), and total and complication costs. Base-case analysis was conducted for eligible patients with type 2 diabetes ≥ 18 years using a Canadian payer perspective with a 25-year time horizon. Future costs and effects were discounted at 3% annually.
RESULTS: RADAR clients experienced higher QALYs (12.69 vs 12.47) than those receiving baseline care. The total cost for RADAR clients (n = 516) was $3971 more per client compared with baseline care. Over the modeled time horizon, the total discounted costs (client management and complications) were higher for RADAR clients than for those receiving baseline care ($16 165 vs $14 463), yielding an incremental cost-effectiveness ratio of $8105 per QALY for RADAR users relative to baseline.
CONCLUSIONS: Our analyses showed that RADAR is potentially cost-effective if the willingness-to-pay threshold of $50 000 per QALY is considered as per the Canadian Agency for Drugs and Technologies in Health guidelines, supporting its value in First Nations care.